Drug delivery into the brain using poly(lactide-co-glycolide) microspheres.
Among the strategies developed for drug delivery into the CNS, locally controlled drug release by the way of an implantable polymeric device has been developed in recent years. The first polymeric devices developed were macroscopic implants needing open surgery for implantation. Over the last few years, poly(lactide-co-glycolide) microspheres have been shown to be safe and promising for drug delivery into the brain. Poly(lactide-co-glycolide) is biodegradable and biocompatible with brain tissue. Due to their size, these microspheres can be easily implanted by stereotaxy in discrete, precise and functional areas of the brain without causing damage to the surrounding -tissue. Brain tumour treatments have been developed using this approach and clinical trials have been performed. Potential applications in neurodegenerative diseases have also been explored, particularly neurotrophic factor delivery and cell therapy.
Menei
Philippe
P
Centre Hospitalo-Universitaire, Departement de Neurochirurgie, Angers, France. phmenei@chu-angers.fr
Montero-Menei
Claudia
C
Venier
Marie-Claire
MC
Benoit
Jean-Pierre
JP
D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000627:therapeutic use; D001672:Biocompatible Materials / Q000737:chemistry*; D001921:Brain / Q000503:physiopathology / Q000601:surgery*; D017690:Cell Transplantation / Q000379:methods; D002986:Clinical Trials as Topic; D004298:Dopamine / Q000008:administration & dosage / Q000627:therapeutic use; D016503:Drug Delivery Systems; D004343:Drug Implants; D005472:Fluorouracil / Q000008:administration & dosage* / Q000627:therapeutic use; D051098:Glial Cell Line-Derived Neurotrophic Factors / Q000008:administration & dosage / Q000627:therapeutic use; D005910:Glioma / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008863:Microspheres; D020932:Nerve Growth Factor / Q000008:administration & dosage / Q000627:therapeutic use; D019636:Neurodegenerative Diseases / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy; D011098:Polyglactin 910 / Q000737:chemistry*; D013238:Stereotaxic Techniques
D000964:Antimetabolites, Antineoplastic; D001672:Biocompatible Materials; D004343:Drug Implants; D051098:Glial Cell Line-Derived Neurotrophic Factors; D011098:Polyglactin 910; D020932:Nerve Growth Factor; D005472:Fluorouracil; D004298:Dopamine